Breast milk antibodies show protection against respiratory viruses

A preparation called LCTG-001 uses secretory IgA to fight viruses like influenza A and respiratory syncytial virus.

Researchers tested LCTG-001, a polyclonal secretory IgA preparation made from pooled human breast milk. This preparation showed broad antiviral activity against respiratory syncytial virus, adenovirus, and influenza A virus.

LCTG-001 recognized influenza A subtypes from group 1 and group 2. This included the highly pathogenic H5N1 clade 2.3.4.4b. It also used neuraminidase inhibition and neutrophil activation.

Secretory IgA is a polyclonal preparation derived from pooled human breast milk. Passive immunization is a tool for protecting individuals with primary immune deficiencies. Mucosal surfaces are the primary entry point for respiratory viruses.

When given intranasally, LCTG-001 provided complete protection against influenza A challenge in murine models. This occurred in both immunocompetent and antibody-deficient models. It prevented morbidity and mortality.

The treatment caused a transient early reduction in viral burden. It also led to sustained improvements in lung pathology and lung barrier integrity. This strategy could address endemic and emerging respiratory viral threats.

Current approaches use intravenous delivery of IgG-enriched plasma or monoclonal antibodies. These methods limit accessibility, scalability, and effectiveness at mucosal surfaces.

Key facts

  • LCTG-001 is a polyclonal secretory IgA preparation from pooled human breast milk.
  • LCTG-001 showed activity against respiratory syncytial virus, adenovirus, and influenza A virus.
  • Intranasal administration of LCTG-001 prevented morbidity and mortality in murine models.

All sections

Edition